EGR1 and irritable bowel syndrome: A deeper understanding of these pathways may guide the development of novel therapies for IBS (e.g., targeting EGR1) and improve the clinical trial design (e.g., excluding participants whose COMT genotype may predispose them to a significant placebo response).